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Abstract
Activation of peroxisome proliferator-activated receptor alpha (PPARa) occurs in animal models of diabetes (DM) and is
implicated in pathological responses to myocardial ischemia. Using bioinformatics, we identified a single nucleotide
polymorphism (SNP) in the PPARa gene promoter (PPARA254,642 G.A; rs135561) that altered the consensus sequence for
a nuclear receptor binding site. Electrophoretic mobility shift assays showed that the domain bound two known PPARA
transcriptional activators, estrogen-related receptor (ERR)-a and -c and that PPARA G bound with greater affinity than PPARA
A (.2-fold; P,0.05). Likewise, promoter-reporter analyses showed enhanced transcriptional activity for PPARA G vs. PPARA A
for both ERR-a and -c (3.1 vs.1.9-fold; P,0.05). Since PPARa activation impairs post-ischemic cardiac function in
experimental models of DM, we tested whether decreased PPARA transcription in PPARA A carriers favorably impacted
outcome after acute coronary ischemia in 705 patients hospitalized with acute coronary syndromes (ACS; 552 Caucasian,
106 African American). PPARA A allele frequencies were similar to non-diseased subjects. However, PPARA genotype
correlated with 5-year mortality in diabetic (22.2% AA vs. 18.8% AG vs. 39.5% GG; P = 0.008), but not non-diabetic (P = 0.96)
subjects (genotype by diabetes interaction P= 0.008). In the diabetic ACS subjects, PPARA A carriers had strikingly reduced
all-cause mortality compared to PPARA G homozygotes, (unadjusted HR 0.44, 95% CI 0.26–0.75; P = 0.003; adjusted HR 0.48,
95% CI 0.27–0.83; P = 0.009). Consistent with previous descriptions of PPARa in experimental models and human disease, we
describe a novel PPARA promoter SNP that decreases transcriptional activation of PPARA and protects against mortality in
diabetic patients after ACS.
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Introduction
Peroxisome proliferator-activated receptor alpha (PPARa) is a
transcription factor involved in the regulated expression of genes
that control fatty acid uptake and metabolism. PPARa is highly
expressed in the heart and other tissues that rely on fatty acid
oxidation as their primary energy substrate [1]. Under normal
conditions, regulation of myocardial PPARa expression and
activity contributes to maintaining homeostatic balance between
cellular fatty acid and glucose utilization via PPARa-mediated
activation of target genes. This balance is perturbed by acute
coronary ischemia [2–11], where myocardial PPARa expression
can be a powerful determinant of functional recovery. For
example, studies in which PPARa gene expression was experi-
mentally manipulated in mouse models have demonstrated that
forced myocardial PPARa overexpression decreases cardiac
recovery after ischemia-reperfusion injury [12], whereas lowering
PPARa expression protects against ischemic damage [12,13].
Accordingly, genetic and epigenetic factors that influence PPARa
gene (PPARA) expression have the potential to modify outcomes
following acute coronary ischemia in patients.
Relevant to the human condition, we and others have suggested
that the pathophysiological impact of PPARa may be greater in
diabetic heart disease [7,8,14]. Insulin resistance and diabetes
mellitus cause a shift of myocardial energy metabolism away from
glucose and toward increased reliance on fatty acids that is driven
in part by activation of PPARa [4,15]. Animal models of diabetes
and obesity, including STZ-induced diabetic rats, db/db mice,
and ob/ob mice, show increased cardiac PPARa activation [15–
17]. Given that cardiac PPARa is activated in DM, such a cardiac
disease-modifier role might have special importance in diabetic
patients. Indeed, a previously described single nucleotide poly-
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morphism (SNP) within intron 1 of PPARA has been associated
with the age of onset, and progression to insulin monotherapy, in
patients with type 2 DM [18], although the biological mechanism
for this effect has not been elucidated. Here, we identify and
characterize a pair of linked SNPs in the 59-flanking promoter
region of human PPARA that modify a consensus nuclear hormone
receptor response element to decrease PPARA transcription. We
found that this genotype confers protection against early post-
ischemic mortality that is specific to diabetic patients. Since these
SNPs are also in linkage disequilibrium (LD) with the previously
described intronic polymorphism, these results also suggest a
mechanism for the clinical effects of that SNP.
Methods
Ethics Statement
The study was approved by the University of Missouri Kansas
City Adult Health Sciences Institutional Review Board, the Saint
Luke’s Hospital of Kansas City Institutional Review Board and the
Washington University Human Research Protection Office
Institutional Review Board. Written informed consent was
provided by each participant. A separate consent form for the
acquisition of blood for genetic analysis was signed by each
participant.
Subjects
Patients were prospectively enrolled into the INFORM ACS
registry at two Kansas City hospitals as previously described
[19,20]. Between 3/1/01 and 10/31/02, 1199 patients met the
criteria for ACS using standard, accepted definitions of MI
(n = 680) and unstable angina (n= 519) [21,22]. MI patients were
defined by an elevated troponin blood test [21]. Patients with DM
were defined by having been given a diagnosis of DM by the
referring physician and/or being treated with oral hypoglycemic
agents or insulin. Three physicians reviewed the charts of all
patients with diagnostic uncertainty and attained consensus on the
final diagnosis.
Although there were no differences in gender (93.2% of men vs.
92.1% of women), Caucasians (91.5% vs. 98.3%, p,0.001) and
older patients (mean age for those consenting = 61613 vs. 65613
for those not consenting, p = 0.004) were less likely to consent to
DNA testing. 726 patients were enrolled in the genetic portion of
this registry, constituting the cohort for the present analysis.
Mortality Assessment
The Social Security Administration Death Master File was
queried to determine patients’ vital status as of 03/12/2008
(http://www.ntis.gov/products/ssa-dmf.asp).
Bioinformatic Analysis
As an initial approach to discovering functionally significant
polymorphisms of the PPARA promoters, we used the web-based
program PromoLign (http://polly.wustl.edu/promolign/main.
html) [23], to identify nucleotide variants within 10 kb of the
transcription start site. This program identifies promoter poly-
morphisms that are within human-mouse homologous blocks and/
or occur within, and alter, the consensus sequences for putative
trans-activating factor binding sites (output shown in Supplemen-
tal Figure S1). We considered that four essential criteria were
necessary to assign functional importance to PPARA promoter
polymorphisms: 1. The bioinformatic SNP had to be validated in a
multi-ethnic human cohort; 2. The putative nuclear receptor
binding domain in which it is located had to bind a transcription
factor; 3.The SNP had to alter binding of that transcription factor;
and 4. The SNP had to change gene transcriptional activity.
Targeted Resequencing
Targeted resequencing of the putative nuclear receptor domain
was performed using pyrosequencing in 380 DNA samples from
unrelated, random, healthy blood donors, 95 each from
Caucasians, African-Americans, Han Chinese, and Mexicans
(Coriell Institute for Medical Research, Camden NJ).
Genotyping
DNA was isolated and extracted using the Puregene genomic
DNA purification kit (Gentra, Minneapolis, MN). The DNA
segments containing the region of interest were amplified with the
polymerase chain reaction (PCR). PCR primers were designed
using Primer3 online software (http://fokker.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) [24], and pyrosequencing primers
were designed using the Pyrosequencing SNP Primer Design
Version 1.01 software (http://www.pyrosequencing.com). Before
use, PCR primer sequences were screened across the human
genome using the NCBI Blast program to ensure their specificity
for the gene of interest. PCR was carried out using Amplitaq Gold
PCR master mix (ABI, Foster City, CA), 1 pmole of each primer
(IDT, Coralville, IA), and 1ng DNA. The PCR primers and
conditions are listed in Supplemental Table S1. Pyrosequencing
was performed using the PSQ HS 96A system with MA v2.0
software as previously described [25]. Data were automatically
transferred from the PSQ HS 96A to a Microsoft Access database
for permanent storage and merging with the clinical datasets
through SAS v9.1. Pair wise linkage (D9) and haplotype analysis
was carried out using the Polymorphism and Haplotype Analysis
Suite [26].
In vitro Studies
Electrophoretic mobility shift assays used standard methodolo-
gies that have been previously described [27,28]. Complementary
oligonucleotides corresponding to the PPARA promoter region
encompassing the SNP of interest were annealed to generate
double-stranded fragments for radiolabeling or cloning. Oligonu-
cleotide sequences were as follows: PPARA 254,642 G forward:
gatcTAGCTCCTGCAGGTTCTCAAGGTTGTAGCCCGCA-
CCCTGCT
PPARA254,642 A forward: gatcTAGCTCCTGCAGGTTCT-
CAAGGTTGTAGTCCACACCCTGCT. Note that these se-
quences differed at two sites, the 254,642 SNP site and at a site 3
nucleotides upstream of this SNP site, due to the upstream site
being in complete LD with the 254,642 SNP site; see results. The
positive control element consisted of the previously characterized
estrogen-related receptor (ERR) responsive element [28]. Probes
were synthesized by Klenow fill-in reaction with [c-32P]dCTP
using the double-stranded fragments and used at 15,000 cpm per
reaction. Binding reactions were performed as described [28]
using recombinant ERRa and ERRc generated from TNT Quick
Coupled T7 reticulocyte lysate (Promega). In competition assays
cold competitor was added at the indicated concentrations
simultaneously with probe and protein. Gels were imaged on a
Storm phosphorimager and band intensities were quantified using
ImageQuant software (Molecular Dynamics).
To clone heterologous PPARA variant promoter-reporter
constructs, (254,642A)2c.TK.Luc and (254,642G)2c.TK.Luc,
double-stranded fragments corresponding to the probes used in
EMSA were 59 phosphorylated then ligated into the BamHI site of
a luciferase expression vector immediately upstream of the
thymidine kinase minimal promoter of the pGL2.TK.Luc reporter
PPARA SNP and Mortality in DM
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plasmid. Clones were screened by PCR and those carrying 2
element copies were verified by sequence analysis. Transient
transfection studies were performed as previously described
[28,29]. PPARA promoter-reporter constructs were cotransfected
with empty expression vector or vector expressing ERRa or
ERRc. Transient transfections in CV1 cells were performed using
Lipofectamine 2000 (Invitrogen) with 2.7 mg/ml reporter, 0.3 mg/
ml each expression vector, and 0.3 mg/ml pRL-CMV to control
for transfection efficiency. C2C12 myoblasts were transfected with
4 mg/ml reporter, 0.5 mg/ml each expression vector, and 0.5 mg/
ml pRL-CMV using the calcium phosphate precipitation method.
Firefly luciferase activity normalized to that of Renilla luciferase
was measured 48h post-transfection on a Clarity luminescence
microplate reader (BioTek) with triplicate determinations in four
trials.
Statistical Analyses
Baseline patient characteristics were summarized and com-
pared stratified by genotype. Hardy-Weinberg equilibrium was
assessed by chi-square in Caucasians and African Americans
separately. Continuous variables were reported as mean 6
standard deviation and compared using t-tests. Lipid values had
skewed distributions, were log-transformed prior to analysis, and
were summarized by median and interquartile range. Categorical
variables were summarized by frequency and percent and
compared using chi-square or Fisher’s exact tests, when the
expected cell size was ,5.
The primary outcome was time to all-cause mortality through
60 months. Event rates by PPARA 254,642 genotype were
calculated using Kaplan-Meier analysis and compared using log-
rank tests. The relative hazard associated with each genotype was
estimated using Cox proportional hazard models, both in crude
analysis and adjusting for demographics (age, gender, race) and
characteristics that were significantly different across genotypes
(systolic BP and treatment strategy).
Proportional hazard assumptions were verified using Schoenfeld
residuals. P-values,0.05 were considered statistically significant.
Analyses were performed using SAS version 9.1 (SAS Institute,
Inc., Cary, NC) and R version 2.2.0.(http://www.R-project.org).
Luciferase activity and binding level values were summarized by
mean and standard error and compared using t-tests. P
values,0.05 were considered statistically significant.
Results
Bioinformatics analysis of PPARA promoters A–D
The PPARa gene (PPARA) has a complex 59 structure,
consisting of four distinct promoter regions designated promoters
A–D [30]. 13 nucleotide variants were identified within 10 kb of
the transcription start site as described in Methods (Table 1 and
Supplemental Figure S1). Of the 13 PPARA promoter polymor-
phisms in the database within human-mouse homologous blocks,
only 2 single nucleotide polymorphisms (SNPs) located 3
nucleotides apart from one another, occurred within, and altered
the consensus sequences for, putative trans-activating factor
binding sites. Of particular interest because of the previously
established important effects of nuclear hormone receptors on
PPARA expression [28,31], was a G to A substitution located 6,862
nucleotides upstream of the major PPARA transcription start site of
promoter A that disrupts a nuclear receptor half-site, designated
PPARA 254,642 G.A (based on its position relative to the
translation initiation site; rs135561). This domain is highly
conserved across vertebrate species, including mouse, rat, rabbit,
dog, chicken, elephant and human (Supplemental Figure S2) and
was therefore selected for further genotyping and analysis.
The PPARA 254,642 A variant is in complete LD with a
PPARA254,645 T variant and is the major allele in African
Americans
Targeted resequencing of the putative nuclear receptor domain
was performed using pyrosequencing in 380 DNA samples from
random, healthy blood donors, 95 each from Caucasians, African-
Americans, Han Chinese, and Mexicans (Coriell Institute for
Medical Research, Camden NJ). The PPARA 254,642 G.A
substitution was confirmed, as was a C to T substitution three
nucleotides 59 (PPARA 254,645 C.T; rs135562) that was in
complete LD (D9=1, r2 = 93, P,0.001) in all ethnic cohorts.
Frequencies of the variant PPARA 254,642 A/PPARA 254,645 T
Table 1. 13 nucleotide variants identified within 10 kb of the PPARA transcription start site located within human-mouse
homologous blocks and/or within consensus sequences for putative trans-activating factor binding sites.
SNP Allele Chromosome 22 Position
TransFac factor binding site(s) in human
sequence around this SNP
rs4823568 A/T 46537906 No
rs135562 A/G 46539636 Yes
rs135561 C/T 46539639 Yes
rs135559 A/G 46539706 No
rs135558 A/2 46540237 No
rs135557 C/T 46541227 No
rs6007947 C/T 46541429 No
rs3052727 2/AGA 46542331 No
rs4044314 A/G 46542403 No
rs2018221 C/T 46542455 No
rs717926 A/C 46542597 No
rs135556 A/G 46543485 No
rs4253781 C/T 46547379 No
doi:10.1371/journal.pone.0012584.t001
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allele were 0.27 in the Caucasian cohort, 0.68 in the African-
American cohort, 0.15 in the Chinese cohort, and 0.12 in the
Mexican cohort, and were each consistent with predictions of
Hardy-Weinberg equilibrium. Thus, the PPARA 254,642 A
variant (and its linked upstream partner) is relatively common in
Caucasians, and is the most common allele in African Americans,
but is relatively uncommon among Mexicans and Asians (#15%).
The PPARA 254,642 G.A SNP alters ERRa and ERRc
binding and PPARA transcriptional activation
Having confirmed the bioinformatics in a multi-racial human
cohort, the next step was to determine if there were any effects of
the PPARA promoter SNP on transcription factor binding and
transcriptional activity. We considered that the most likely factors
to bind to the PPARA nuclear receptor half-site were estrogen
related receptor (ERR)a and ERRc, based on the characteristic
nucleotide sequence [32,33], on known similarities in tissue
expression between ERR and PPARa [34–36], and on ERR
regulatory activities for genes downstream of PPARa [28,35,36].
To test ERR binding, a 49 bp double-stranded (ds) oligonucleotide
was generated corresponding to the ‘wild-type’ form of PPARA
254,642 (G) and 254,645 (C). Electrophoretic mobility shift
assays (EMSA) were performed to compare binding of recombi-
nant ERRa and ERRc proteins between 32P-labeled PPARA and
authentic, previously described ERR binding sequences [28]. Both
ERRa and ERRc bound the wild-type PPARA 254,642 G
sequence with activities equal to, or greater than, the control ERR
responsive element (Probe G vs. +control; Figure 1A).
We next examined relative ERR binding in EMSA studies
performed with the same wild-type PPARA 254,642 G probe
described above and a ‘variant’ PPARA 254,642 A probe,
identical in sequence except for the nucleotides encoding the
two linked SNPs (A at nucleotide 254,642 and T at nucleotide
254,645, respectively). The apparent binding of both ERRa and
ERRc for the variant PPARA 254,642 A probe was qualitatively
less than for the wild-type G probe (Probe A vs. Probe G;
Figure 1A). The relative affinity of ERRa for the wild-type and
variant sequences was assessed in competition binding studies
using increasing amounts of unlabeled G or A dsDNA probe to
displace wild-type G probe in the EMSA binding reactions. The
variant A probe competed less effectively for binding to the 32P-
labelled wild-type sequence (IC50 of A probe 2.3-fold greater than
G probe, P,0.05), demonstrating a lower affinity for ERRa
(Figure 1B and 1C) and ERRc (data not shown). Thus, the G.A
substitution decreases PPARA promoter affinity for the transcrip-
tion factors ERRa and ERRc.
To determine whether the decrease in ERR binding afforded by
the PPARA 254,642 G.A polymorphism altered transcriptional
activity, we performed reporter assays. The reporter constructs
contained two copies of either the wild-type G or the variant A
49 bp promoter element inserted upstream of a minimal
thymidine kinase (TK) promoter-luciferase reporter [29]. When
co-transfected with an ERRa expression plasmid into C2C12
myoblasts, which are a useful in vitro model of skeletal and cardiac
muscle [37], the variant A promoter-reporter was ,25% less
responsive to ERRa-mediated activation than the wild-type G
Figure 1. PPARA 254,642 A variant binds ERRa and ERRc with less affinity. (A) Electrophorectic mobility shift assay of binding activity
performed with 32P-labeled probes differing at the PPARA 254,642 SNP sites (with the corresponding linked 254,645 SNP; see methods) using
recombinant ERRa and ERRc proteins. (B) Competition experiments performed with PPARA254,642 G probe incubated with 10-fold, 50-fold and 100-
fold excess of unlabeled G probe or unlabeled A probe as a competitor. Mean relative band intensities (representative trial, top) from 3 trials were
quantified by phosphorimage analysis and results are depicted graphically in the bottom panel. Asterisks represent significantly different binding to
probe compared to control (p,0.05).
doi:10.1371/journal.pone.0012584.g001
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promoter-reporter (p,0.05; n= 4; Figure 2A). Similar decreased
activation of variant PPARA 254,642 A was observed with ERRc
co-transfection (data not shown).
To control for the possibility that endogenous ERRa in C2C12
myoblasts was masking PPARA/TK A promoter-reporter activa-
tion by transfected ERRa, we repeated the experiments in CV1
cells that are null for endogenous ERRa and ERRc [28]. In the
CV1 system the wild-type G PPARA promoter-reporter had,60%
greater responsiveness to ERRa-mediated activation than the A
variant promoter-reporter (3.1-fold vs.1.9-fold; P,0.05; n= 4,
Figure 2B). Again, the results were similar with co-transfection of
ERRc (data not shown). These studies demonstrate that the
variant PPARA promoter sequence exhibits diminished ERR
binding and decreased ERR-mediated transcriptional activation,
compared to the wild-type PPARA 254,642 G allele.
In diabetic patients, PPARA -54,642 A allele carriers have
deceased mortality after acute coronary ischemia
The above studies demonstrate clear biological effects of the
PPARA 254,642 G.A promoter polymorphism: The more
common (in Caucasians) PPARA G promoter is more responsive
to ERR, while the variant A promoter is less effective at binding
ERR and is therefore resistant to ERR-mediated transcription.
Since we have previously shown that cardiac PPARa is activated in
experimental DM [15], and that such PPARa activation is
deleterious during experimental myocardial ischemia [38–49], we
hypothesized that diminished PPARa gene activity conferred by the
254,642 A variant might have the opposite effect, i.e. be protective,
in human subjects with acute coronary ischemic syndromes (ACS).
We tested this idea in the 726 subject genetic sub-study of the
INFORM trial of outcomes after ACS [19]. Baseline clinical and
demographic data for the 705 patients (96%) for whom genotypes
were obtained are listed in Table 2, and for patients with DM
stratified by PPARA promoter genotype in Table 3. The PPARA
254,642 A allele frequency in ACS patients was 0.30 in Caucasians
and 0.60 in African-Americans, which is not significantly different
from the frequencies in the healthy volunteers used for SNP
validation (P= 0.53 and =0.26, respectively; see above), and
suggests that the PPARA SNP is not an independent risk factor for
cardiac ischemic disease. As in the non-diseased cohort, the
adjacent PPARA 254,645 C.T SNP (rs135562) was found to be
in complete LD (D9=1, r2 = 93, P,0.001) in both Caucasian and
African-American subgroups, and did not deviate significantly from
Hardy-Weinberg equilibrium.
To determine if the PPARA promoter variant modified outcome
in patients with acute coronary ischemic syndromes we examined
the relationship between PPARA 254,642 (rs135561) genotype
and five year mortality in the INFORM study. When DM status
was not a co-variate, there was no apparent association. However,
when the cohort was stratified by DM status, PPARA 254,642
genotype was associated with increased 5-year mortality in
diabetic (p = 0.008) but not in non-diabetic (p = 0.96) ACS patients
(Figure 3; genotype by DM interaction p= 0.008). In non-diabetic
ACS patients, 5-year mortality was 13.5% for wild-type PPARA
GG homozygous subjects, and 12.7% for variant PPARA A allele
carriers (Figure 3B). Consistent with the known adverse effects on
ACS outcome of having diabetes [50–52], homozygous 254,642
GG (wild-type) PPARA ACS patients had a 5-year mortality rate of
39.5% (Figure 3A). By contrast, PPARA variant A allele carriers
(AG or AA) had a 5-year mortality rate following admission for
Figure 2. PPARA 254,642 A variant is less responsive to ERR-mediated co-activation. Mean normalized luciferase activities (6SE) in (A)
C2C12 myobalst cells or (B) CV1 cells cotransfected with PPARA 254,642 A or PPARA 254,642 G promoter-reporter constructs +/2 a mammalian
expression vector that overexpresses ERRa as indicated. Asterisks represent significantly different transcriptional activation compared to vector
control (p,0.05). Four independent trials were performed in triplicate for each cell line.
doi:10.1371/journal.pone.0012584.g002
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ACS of 19.9% (Figure 3A and Table 4; HR 0.44, 95% CI 0.26–
0.75; P= 0.003), demonstrating a striking protective effect of the
PPARA promoter polymorphism. When adjusted for age, race, and
gender, genotype remained an independent predictor of 5-year
mortality, with PPARA 254,642 A allele carriers having less than
half the relative risk of death within 5 years of presenting with
ACS, compared to wild-type (homozygous PPARA 254,642 GG
genotype) diabetics (HR 0.48, 95% CI 0.27–0.83; p = 0.009). This
relationship was not changed by further adjusting for any other
variable that differed significantly between genotype groups (HR
0.48, 95% CI 0.26–0.89; p= 0.019). Notwithstanding the
differences in PPARA 254,642 allele frequency between Cauca-
sians and African-Americans, in Caucasian DM subjects alone (the
largest racial group) PPARA 254,642 A carriers were significantly
protected against 5-year mortality compared to wild-type GG
allele patients (unadjusted HR 0.47, 95% CI 0.24–0.90; P = 0.023;
adjusted HR 0.46, 95% CI 0.24–0.89; P= 0.021; Table 4).
As mentioned above, an A.C SNP (rs135539) located in intron
1 (promoter B) of PPARA, 35,014 base pairs upstream of the
translation start site, has been reported to influence the age of
onset and progression to insulin monotherapy in patients with type
2 DM [18]. Although the authors provided no mechanism to
explain these findings, they speculated that C allele carriers had
reduced PPARa expression [18]. To evaluate whether PPARA
235,014 genotype impacted our findings, we genotyped the 726
subject genetic substudy of the INFORM trial for this polymor-
phism and found that the two SNPs (PPARA 254,642 and PPARA
235,014) were in moderate LD (D9=0.58, r2 = 17, P,0.001
Caucasians; D9=0.78, r2 = 39, P,0.001 African Americans). In
addition, we found a borderline significant association with
mortality in diabetic subjects within our cohort (unadjusted
P= 0.051; AA vs. AC vs CC). Although this association only
achieved borderline significance, there was a highly significant
genotype by diabetes interaction (p= 0.009).
Discussion
The current results define a new genetic disease modifier of
outcome after cardiac ischemia that is specific for diabetes and
suggests a biologic mechanism for the previously described PPARA
intronic SNP. We used bioinformatics to identify candidate SNPs
with the potential to modify transcription factor binding and high
homology to mouse promoter regions in the four PPARA
promoters. One candidate, the PPARA 254,642 (rs135561)
G.A polymorphism, interrupted a putative nuclear factor biding
domain and altered binding of two critical regulatory factors for
PPARA expression, ERRa and ERRc. In vitro promoter-reporter
assays revealed that this effect changed transcriptional activity of
the PPARA promoter, and our clinical association studies revealed
a significant impact on 5-year mortality in patients with DM and
acute coronary ischemia.
We took advantage of an experiment of nature, a common pair
of SNPs that alter PPARA promoter activity, to demonstrate that
PPARA expression level helps determine outcome after myocardial
infarction and unstable angina in human subjects with DM. This
result is consistent with previous findings in genetic mouse models
that PPARa expression level inversely correlates with post-
ischemic cardiac function [12] and extends the previous report
of an association between PPARA 235,014 (rs135539) and onset
and progression of DM [18]. Taken together, the human, mouse,
and cell culture studies represent a comprehensive evaluation of
PPARa effects in ischemic hearts.
A growing body of evidence describes associations between the
PPARa gene and cardiovascular disease, risk or outcomes in
subjects with type 2 DM [18,53–58]. Of particular relevance to the
current findings is the A.C SNP (rs135539) located in intron 1 of
PPARA reported to influence the age of onset and progression to
insulin monotherapy in patients with type 2 DM [18]. No
mechanism has been forthcoming to explain these findings but the
authors speculated that C allele carriers had reduced PPARa
expression [18]. The current results suggest an alternate
explanation for the previously described associations with the
PPARA intronic SNP and provide evidence to support the authors’
hypothesis that C allele carriers have reduced PPARa expression.
Increased risk of mortality after ACS in patients with DM has
been recognized for many years [38–41,43,45], but the specific
reasons for this adverse outcome are unknown. It is notable that
the recent therapeutic advances that have improved general
outcomes in ACS, have not impacted the disparity in outcomes in
diabetic individuals [42,44,46–49]. Data from clinical trials also
suggest that PPAR activation with pharmacological agonists








African American 126 (17.9%)
Other 27 (3.8%)
Prior MI 236 (33.5%)
Prior PCI 221 (31.3%)
Prior CABG 128 (18.2%)
Chronic HF 55 (7.8%)
HTN 464 (65.8%)
Hyperlipidemia 427 (60.6%)
DM Known on Arrival 200 (28.4%)
Admit BMI 29.666.3







Cardiac catheterization 576 (81.7%)
Treatment
Medical management 264 (37.4%)
PCI 409 (58.0%)
CABG 32 (4.5%)
Discharge Medications - BB 566 (80.5%)
Abbreviations: MI myocardial infarction, PCI percutaneous coronary
intervention, CABG coronary artery bypass graft, HF heart failure, HTN
hypertension, DM diabetes mellitus, BMI body-mass index, BP blood pressure,
EF ejection fraction, ACS acute coronary syndrome, STEMI ST-elevation
myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, USA
unstable angina, BB beta-blockers.
doi:10.1371/journal.pone.0012584.t002
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Table 3. Clinical Characteristics of the Diabetic INFORM ACS Cohort according to PPARA 254,642 genotype.
PPARA 254,642 AG
Patient Characteristics by Genotype AA (n=36) AG (n=75) GG (n=89) p-values
Age (mean +/2 SD) 57.4+/211.0 59.1+/211.5 61.4+/210.3 0.132
Sex 0.659
Male 22 (61.1%) 39 (52.0%) 48 (53.9%)
Female 14 (38.9%) 36 (48.0%) 41 (46.1%)
Race ,0.001
Caucasian 16 (44.4%) 48 (64.0%) 72 (80.9%)
African American 19 (52.8%) 26 (34.7%) 9 (10.1%)
Other 1 (2.8%) 1 (1.3%) 8 (9.0%)
HTN 29 (80.6%) 56 (74.7%) 79 (88.8%) 0.063
Admit BMI (mean +/2 SD) 33.4+/27.8 32.2+/26.9 32.0+/26.9 0.599
Admit systolic BP (mean +/2 SD) 141.8+/232.5 143.5+/225.9 132.4+/226.5 0.028
EF,40% 7 (20.0%) 18 (26.9%) 21 (26.3%) 0.724
Admit Glucose (mean +/2 SD) 261.7+/2198.9 183.5+/281.4 206.2+/2106.7 0.065
ACS Type 0.938
STEMI 8 (22.2%) 16 (21.3%) 19 (21.3%)
NSTEMI 11 (30.6%) 20 (26.7%) 29 (32.6%)
USA 17 (47.2%) 39 (52.0%) 41 (46.1%)
Treatment 0.022
Medical management 22 (61.1%) 39 (52.0%) 34 (38.2%)
PCI [acute or other] 11 (30.6%) 33 (44.0%) 53 (59.6%)
CABG 3 (8.3%) 3 (4.0%) 2 (2.2%)
Discharge Medications -BB 27 (75.0%) 63 (85.1%) 67 (75.3%) 0.252
Abbreviations: HTN hypertension, BMI body-mass index, BP blood pressure, EF ejection fraction, ACS acute coronary syndrome, STEMI ST-elevation myocardial
infarction, NSTEMI non-ST-elevation myocardial infarction, USA unstable angina, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, BB beta
blocker.
doi:10.1371/journal.pone.0012584.t003
Figure 3. In diabetic patients, PPARA 254,642 A allele carriers have deceased mortality after acute coronary ischemia. Kaplan-Meier
estimates of mortality stratified by PPARA254,642 genotype in patients with (A) and without (B) DM. p-values between genotype groups are shown.
(p-value for genotype by diabetes interaction = 0.008).
doi:10.1371/journal.pone.0012584.g003
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increases the risk of myocardial infarction and adverse cardiovas-
cular events in patients with DM [59,60]. Since our results identify
a gene-disease interaction that alters mortality specifically in the
diabetic population after cardiac ischemia, they suggest that a
therapeutic approach targeting PPAR-responsive genes and
metabolic pathways might favorably affect outcomes.
Our studies suggest that modified ERR binding is a mechanism
for altered PPARA expression in the polymorphic promoter, but
there is scant available data on factors that affect ERRa and
ERRc mRNA or protein expression levels in vivo. We previously
found that ERRa and ERRc activate PPARA expression via direct
binding to PPARA promoter B (249,076 to 249,064 upstream of
the translation start site) [28] and observed that myocardial ERRa
transcript expression is developmentally regulated in parallel with
PPARa [61]. Interestingly, myocardial ERRa transcript expres-
sion is also up-regulated in animals fed high fat diets and in animal
models of insulin-deficient DM (Huss, unpublished observation),
providing further circumstantial evidence for a link between
PPARa, ERR, and DM.
Our findings should be considered in the context of some
potential limitations. Although genotype remained an independent
predictor of 5-year mortality in both unadjusted and adjusted
analyses, as well as in subgroup analyses performed in our largest
racial group (Caucasians), replication in other studies is still
warranted. Furthermore, our findings cannot be extrapolated to
racial groups other than those represented in INFORM
(Caucasians and African Americans) and should, therefore, be
examined independently in other racial groups.
In conclusion, we have identified a PPARA promoter polymor-
phism that effects binding and activation of PPARA co-activators
and is strongly associated with 5-year mortality in diabetic ACS
patients. These findings suggest a genetic mechanism for the
unfavorable cardiovascular outcomes in diabetic patients after
ACS.
Supporting Information
Table S1 PCR and Pyrosequencing primers and conditions.
Found at: doi:10.1371/journal.pone.0012584.s001 (0.04 MB
DOC)
Figure S1 Output of the web-based program PromoLign
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